Literature DB >> 23364580

Improvement of therapeutic compliance in haemodialysis patients with poor phosphorus control and adherence to treatment with binders: COMQUELFOS study.

M Dolores Arenas1, Rafael Pérez-García, Mazine Bennouna, Ana Blanco, Oscar Mauricio, M Dolores Prados, José L Lerma, M Luisa Muñiz, M Belén Martín.   

Abstract

BACKGROUND: The effectiveness of phosphate binders in daily practice is directly related to therapeutic compliance (TC) by the patient. The goal of this study was to analyse the TC of haemodialysis patients with hyperphosphatemia and its influence on serum phosphorus for 6 months follow up.
METHODS: 181 patients were included, who had mean initial phosphate levels (P) >5mg/dl. TC with different phosphate binders was evaluated, considering non-adherent patients those who had <75% of TC, SMAQ scale score of "non-adherent"(Table 1), and P>5mg/dl. Patients who were adherent at baseline visit (BV) left the study, the rest continued to V5 (6 months). TC at baseline and during the follow up (V1-V5) was analysed. Phosphate binders and the evolution of phosphataemia based on treatment were assessed.
RESULTS: 103 male and 78 female patients were evaluated, with a mean age of 59.9 (21-86) years. Of these, 39.2% (n=71) were adherent in the BV. Patients older than 60 years of age were more adherent than younger ones (P=.019).Table 6 specifies the causes of non-compliance. The remaining 60.8% of patients (n=110), were non-adherent and continued through to the end of the study. An average of 27.2% of these patients became adherent during the course of the study. Table 7 shows the relative levels of P with TC over successive visits. At the end of the study, mean P levels had decreased by 1.26mg/dl (P<.0001).
CONCLUSION: Among HD patients with poor P level control, there is a low level of adherence with phosphorus binder treatment, at 39.2%. Compliance and phosphataemia are improved with different strategies. The decrease of P is higher in adherent patients than in non-adherent patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23364580     DOI: 10.3265/Nefrologia.pre2012.Oct.11726

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  6 in total

1.  Self-Motivation Is Associated With Phosphorus Control in End-Stage Renal Disease.

Authors:  Ebele M Umeukeje; Joseph R Merighi; Teri Browne; Jacquelyn N Victoroff; Kausik Umanath; Julia B Lewis; T Alp Ikizler; Kenneth A Wallston; Kerri Cavanaugh
Journal:  J Ren Nutr       Date:  2015-04-22       Impact factor: 3.655

2.  An Analysis of Medication Adherence and Patient Preference in Long-term Stable Maintenance Hemodialysis Patients in Japan.

Authors:  Masaki Ohya; Yuko Iwashita; Satoko Kunimoto; Shuto Yamamoto; Toru Mima; Shigeo Negi; Takashi Shigematsu
Journal:  Intern Med       Date:  2019-06-07       Impact factor: 1.271

Review 3.  Nonadherence to Medication Therapy in Haemodialysis Patients: A Systematic Review.

Authors:  Saurav Ghimire; Ronald L Castelino; Nicole M Lioufas; Gregory M Peterson; Syed Tabish R Zaidi
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

Review 4.  Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence.

Authors:  M Jesús Lloret; César Ruiz-García; Iara Dasilva; Mónica Furlano; Yaima Barreiro; José Ballarín; Jordi Bover
Journal:  Patient Prefer Adherence       Date:  2013-11-06       Impact factor: 2.711

Review 5.  Phosphate-control adherence in hemodialysis patients: current perspectives.

Authors:  Ebele M Umeukeje; Amanda S Mixon; Kerri L Cavanaugh
Journal:  Patient Prefer Adherence       Date:  2018-07-04       Impact factor: 2.711

6.  Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study.

Authors:  Juan F Navarro-González; María Dolores Arenas; Fernando Henríquez-Palop; María Jesús Lloret; Pablo Molina; Francisco Ríos Moreno; María Asunción Macia-Lagier; Laura Espinel; Emilio Sánchez; Mar Lago; Antonio Crespo; Jordi Bover
Journal:  Clin Kidney J       Date:  2021-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.